Our story
Ziphius is named after the rare dolphin Ziphius cavirostris. This dolphin is most known for undertaking the deepest and longest dives recorded.
Ziphius is a biopharmaceutical company, dedicated to develop saRNA vaccines and therapeutics. Ziphius focuses on both vaccines for infectious diseases and gene supplementation therapies for rare genetic disorders.
Since our founding in 2019, Ziphius has worked to develop and validate its self-amplifying RNA and LNP platforms. Currently, these platforms are being used to rapidly expand our pipeline and move forward multiple preclinical development programs towards the clinic.
Our mission
Our mission is to reduce the global impact of infectious and rare genetic diseases through the innovative application of self-amplifying RNA (saRNA) in our Platform Technology.
Our values
Caring, Positivity, Growth, Integrity, Unity and Passion
